Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-761-4904
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions
What is Aldeyra Therapeutics' stock symbol?
Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."
How were Aldeyra Therapeutics' earnings last quarter?
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) posted its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.02. View Aldeyra Therapeutics' Earnings History.
When is Aldeyra Therapeutics' next earnings date?
What price target have analysts set for ALDX?
5 brokers have issued 1-year price targets for Aldeyra Therapeutics' stock. Their predictions range from $20.00 to $38.00. On average, they anticipate Aldeyra Therapeutics' share price to reach $31.40 in the next year. This suggests a possible upside of 336.1% from the stock's current price. View Analyst Price Targets for Aldeyra Therapeutics.
What is the consensus analysts' recommendation for Aldeyra Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aldeyra Therapeutics.
What are Wall Street analysts saying about Aldeyra Therapeutics stock?
Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:
- 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (5/8/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and raise the 12-month price target to $35/share from $30 following the announcement of the successful pivotal ALLEVIATE trial data in allergic conjunctivitis (AC)." (3/26/2019)
Has Aldeyra Therapeutics been receiving favorable news coverage?
News stories about ALDX stock have been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aldeyra Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Aldeyra Therapeutics' key competitors?
Some companies that are related to Aldeyra Therapeutics include TherapeuticsMD (TXMD), Retrophin (RTRX), CannTrust (CNTTF), Axsome Therapeutics (AXSM), Principia Biopharma (PRNB), Eagle Pharmaceuticals (EGRX), Cara Therapeutics (CARA), ArQule (ARQL), Y-mAbs Therapeutics (YMAB), ChemoCentryx (CCXI), Arvinas (ARVN), Vectura Group (VEGPF), Aptorum Group (APM), ZIOPHARM Oncology (ZIOP) and Intra-Cellular Therapies (ITCI).
What other stocks do shareholders of Aldeyra Therapeutics own?
Who are Aldeyra Therapeutics' key executives?
Aldeyra Therapeutics' management team includes the folowing people:
- Dr. Todd C. Brady, Chief Exec. Officer, Pres and Director (Age 46)
- Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer and Treasurer (Age 59)
- Dr. David J. Clark M.D., M.R.C.P., A.F.P.M., Chief Medical Officer (Age 53)
- Ms. Mary Taylor M.P.H., Sr. VP of Regulatory Affairs (Age 59)
Who are Aldeyra Therapeutics' major shareholders?
Aldeyra Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (6.90%), BlackRock Inc. (4.88%), Northern Trust Corp (1.01%), Geode Capital Management LLC (1.00%), Gilder Gagnon Howe & Co. LLC (0.80%) and Prescott Group Capital Management L.L.C. (0.38%). Company insiders that own Aldeyra Therapeutics stock include Jesse I Treu and Life Sciences Maste Perceptive. View Institutional Ownership Trends for Aldeyra Therapeutics.
Which major investors are selling Aldeyra Therapeutics stock?
ALDX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, JPMorgan Chase & Co., Hikari Power Ltd, Oxford Asset Management LLP, Algert Global LLC, Charles Schwab Investment Management Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Aldeyra Therapeutics.
Which major investors are buying Aldeyra Therapeutics stock?
ALDX stock was purchased by a variety of institutional investors in the last quarter, including Prescott Group Capital Management L.L.C., BlackRock Inc., Connor Clark & Lunn Investment Management Ltd., Geode Capital Management LLC, Strs Ohio, Thompson Siegel & Walmsley LLC, Trexquant Investment LP and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for Aldeyra Therapeutics.
How do I buy shares of Aldeyra Therapeutics?
Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aldeyra Therapeutics' stock price today?
One share of ALDX stock can currently be purchased for approximately $7.20.
How big of a company is Aldeyra Therapeutics?
Aldeyra Therapeutics has a market capitalization of $197.93 million. The biotechnology company earns $-38,890,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.
What is Aldeyra Therapeutics' official website?
How can I contact Aldeyra Therapeutics?
Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]
MarketBeat Community Rating for Aldeyra Therapeutics (NASDAQ ALDX)
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe ALDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
